Before 2011, when checkpoint inhibitor treatments became available, the median survival for people with advanced melanoma was 11 months. The final results of the Checkmate 067 study, just published in the New England Journal of Medicine , confirms the dramatic improvements in survival since then. The phase 3 study randomised 945 people with stage III or IV melanoma to receive either the checkpoint inhibitors nivolumab plus ipilimumab, nivolumab with placebo, or ipilimumab with placebo. Median survival in those allocated to nivolumab plus ipilimumab was 71.9 months, and 10 year overall survival was 43% with nivolumab plus ipilimumab, 37% with nivolumab, and 19% with ipilimumab.
Tom Nolan is a clinical editor at various esteemed publications. He specializes in medicine and healthcare, with a focus on medical specialties and alternative medicine, while also exploring topics such as crime, Brazil, books, and Tokyo. His work has been featured in The Wall Street Journal, The Art Newspaper, Guitar World, and many other notable outlets.